Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Category: 2021
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
20211109 – Transgene BioInvent SITC BT-001 en
Transgene reports business update and Q3 2021 financial position
20211104 – Transgene – Q3 Financial update EN
Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
BT-001 oncolytic virus at SITC 2021
Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation
Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
Transgene Announces Upcoming Investor Meetings
Transgene Announces Upcoming Investor Meetings
Transgene Participates in New Cancer Research Consortium
Transgene Participates in New Cancer Research Consortium
